Immunosuppressants API Market
Immunosuppressants API Market Size, Share, and Trends Analysis Report, By Type (Corticosteroids, Janus Kinase Inhibitor, Calcineurin Inhibitors, mTOR Inhibitor, and Others), By Method (Synthetic Chemistry, Peptide Chemistry, Fermentation, and Chromatographic Purification), By Application (Autoimmune Disease and Organ Transplant), By Product (Tablets, Capsules, Liquids, and Injections), By End-User (Biotechnology & Biopharmaceutical Company, CMOs, CROs, CDMOs, and Other), Forecast Period (2022-2028)
Immunosuppressants API market is anticipated to grow at a CAGR of 8.2% during the forecast period. The rising number of organ transplants globally is one of the prominent factors that has surged the demand for immunosuppressant API drugs. Immunosuppressants help prevent organ rejection. As per the United Network for Organ Sharing, in 2021, around 41,355 organ transplants were performed. Of which 24,670; 9,236; 3,817; and 2,524 accounted for kidney, liver, heart, and lung respectively. In addition, 106,131 people need a lifesaving organ transplant, of which people need a lifesaving organ transplant. Constant technological advancements in tissue engineering are also crucial factors enhancing the overall market development. The market growth is also backed by the growing geriatric population, increasing prevalence of autoimmune diseases, and rapid growth in the biopharmaceuticals sector.
However, certain factors that can act as major impediments to the growth of the market include the high costs associated with API and the lack of availability of organ donors. Moreover, rising US FDA drug approvals can bring new growth opportunities for the market players. For instance, in August 2019, AbbVie, a research-based global biopharmaceutical company got US FDA approval from RINVOQ (upadacitinib), a once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
Segmental Outlook
The global immunosuppressants API market is segmented based on type, method, application, product, and end-user. Based on type, the market is sub-segmented into corticosteroids, Janus kinase inhibitors, calcineurin inhibitors, mTOR inhibitors, and others. Among these, the mTOR inhibitor is expected to be the fastest growing in the global immunosuppressants API market. An mTOR inhibitor immunosuppressant is used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors. The mammalian target of the rapamycin (mTOR) pathway plays a central role in the activation and proliferation of T cells. The mTOR inhibitor, rapamycin, has been used clinically to prevent graft rejection since being approved for use in transplantation in 1999. With the increase in organ transplants, the segment is expected to gain a high share during the forecast period.
Based on the method, the market is sub-segmented into synthetic chemistry, peptide chemistry, fermentation, and chromatographic purification. Similarly, based on application, it is bifurcated into autoimmune disease and organ transplant. The autoimmune disease segment held the largest market share in 2021 and is forecast to register higher growth during the forecast period owing to the growing prevalence of autoimmune diseases globally.
Based on product, the market is further classified into tablets, capsules, liquids, and injections. Whereas based on end-user, the global immunosuppressants API market is divided into biotechnology & biopharmaceutical companies, CMOS, CROS, CDMOS, and others.
Regional Outlook
Geographically, the global immunosuppressants API market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). The Asia-Pacific region is expected to be the fastest-growing region in the immunosuppressants API market during the forecast period. The regional growth is attributed to the increase in per capita income, rise in government initiatives for better healthcare infrastructure, and strong presence of major players aiming on expanding their geographical presence in the region’s major economies. Apart from these factors, the rise in demand for organ transplants and the high prevalence of arthritis and irritable bowel syndrome are the other prominent factor generating the significant demand for Immunosuppressants API.
Global Immunosuppressants API Market Growth, By Region 2022-2028
North America Holds the Largest Share in Immunosuppressants API Market
Geographically, the North American region held the highest market share in 2021. The region is estimated to dominate by accounting for a significant share in upcoming years. The surging incidence of autoimmune disorders such as multiple sclerosis, alopecia areata, and arthritis is positively impacting the growth of the market in the North American region. In addition, an increase in organ transplants such as liver & kidney transplants is also accelerating the market growth. As per the United Network for Organ Sharing (UNOS), in 2021, around 41,354 organ transplants were performed in the US, an increase of 5.9 percent over 2020. There was a total of 24,669 kidney transplants, 9,236 liver transplants, and 3,817 heart transplants. Moreover, a total of 5,725 living donor transplants were performed in 2020, a decrease of 22.6 percent over the record of 7,397 set in 2019 due to the COVID-19 pandemic. This has surged the demand for Immunosuppressants APIs, as transplant patients need immunosuppressant drugs to prevent the immune system from rejecting the new organ. This led to market growth.
Market Players Outlook
The major market players in the global immunosuppressants API market include Biocon Ltd., Concord Biotech Ltd., Pfizer Inc., RPG Life Science Ltd., and Zhejiang Hisun Pharmaceutical Co. Ltd., among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global immunosuppressants API market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Immunosuppressants API Market by Type
4.1.1. Corticosteroids
4.1.2. Janus Kinase Inhibitor
4.1.3. Calcineurin Inhibitors
4.1.4. mTOR Inhibitor
4.1.5. Others
4.2. Global Immunosuppressants API Market by Method
4.2.1. Synthetic Chemistry
4.2.2. Peptide Chemistry
4.2.3. Fermentation
4.2.4. Chromatographic Purification
4.3. Global Immunosuppressants API Market by Application
4.3.1. Autoimmune Disease
4.3.2. Organ Transplant
4.4. Global Immunosuppressants API Market by Product
4.4.1. Tablets
4.4.2. Capsules
4.4.3. Liquids
4.4.4. Injections
4.5. Global Immunosuppressants API Market by End-User
4.5.1. Biotechnology & Biopharmaceutical Co.
4.5.2. CMOs
4.5.3. CROs
4.5.4. CDMOs
4.5.5. Other
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
5.4.1. Latin America
5.4.2. Middle East & Africa
6. Company Profiles
6.1. AbbVie, Inc.
6.2. Accord Healthcare, Ltd.
6.3. Biocon, Ltd.
6.4. Bristol-Myers Squibb, Co.
6.5. Chunghwa Chemical Synthesis & Biotech Co. Ltd.
6.6. Concord Biotech, Ltd.
6.7. GlaxoSmithKline PLC
6.8. Glenmark Pharmaceuticals, Inc.
6.9. Hoffmann-La Roche AG.
6.10. Jiangsu Jiuyang Bio-Pharmaceutical Co. Ltd
6.11. NATCO Pharma, Ltd.
6.12. Pfizer, Inc.
6.13. RPG Life Sciences, Ltd.
6.14. Triveni Interchem Pvt., Ltd.
6.15. Zhejiang Hisun Pharmaceutical Co. Ltd.
1. GLOBAL IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL CORTICOSTEROIDS IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL JANUS KINASE INHIBITOR IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL CALCINEURIN INHIBITORS IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL MTOR INHIBITOR IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL OTHERS IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY METHOD, 2021-2028 ($ MILLION)
8. GLOBAL SYNTHETIC CHEMISTRY IN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL PEPTIDE CHEMISTRY IN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL FERMENTATION IN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL CHROMATOGRAPHIC PURIFICATION IN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
13. GLOBAL IMMUNOSUPPRESSANTS API IN AUTOIMMUNE DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL IMMUNOSUPPRESSANTS API IN ORGAN TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
16. GLOBAL IMMUNOSUPPRESSANTS API TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17. GLOBAL IMMUNOSUPPRESSANTS API CAPSULES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
18. GLOBAL IMMUNOSUPPRESSANTS API LIQUIDS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
19. GLOBAL IMMUNOSUPPRESSANTS API INJECTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
20. GLOBAL IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
21. GLOBAL IMMUNOSUPPRESSANTS API BY BIOTECHNOLOGY & BIOPHARMACEUTICAL COMPANY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
22. GLOBAL IMMUNOSUPPRESSANTS API BY CMOS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
23. GLOBAL IMMUNOSUPPRESSANTS API BY CROS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
24. GLOBAL IMMUNOSUPPRESSANTS API BY CDMOS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
25. GLOBAL IMMUNOSUPPRESSANTS API BY OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
26. GLOBAL IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
27. NORTH AMERICAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
28. NORTH AMERICAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
29. NORTH AMERICAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY METHOD, 2021-2028 ($ MILLION)
30. NORTH AMERICAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
31. NORTH AMERICAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
32. NORTH AMERICAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
33. EUROPEAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
34. EUROPEAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
35. EUROPEAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY METHOD, 2021-2028 ($ MILLION)
36. EUROPEAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
37. EUROPEAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
38. EUROPEAN IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
39. ASIA-PACIFIC IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
40. ASIA-PACIFIC IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
41. ASIA-PACIFIC IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY METHOD, 2021-2028 ($ MILLION)
42. ASIA-PACIFIC IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
43. ASIA-PACIFIC IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
44. ASIA-PACIFIC IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
45. REST OF THE WORLD IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
46. REST OF THE WORLD IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
47. REST OF THE WORLD IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY METHOD, 2021-2028 ($ MILLION)
48. REST OF THE WORLD IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
49. REST OF THE WORLD IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
50. REST OF THE WORLD IMMUNOSUPPRESSANTS API MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. GLOBAL IMMUNOSUPPRESSANTS API MARKET SHARE BY TYPE, 2021 VS 2028 (%)
2. GLOBAL IMMUNOSUPPRESSANTS API MARKET SHARE BY METHOD, 2021 VS 2028 (%)
3. GLOBAL IMMUNOSUPPRESSANTS API MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
4. GLOBAL IMMUNOSUPPRESSANTS API MARKET SHARE BY PRODUCT, 2021 VS 2028 (%)
5. GLOBAL IMMUNOSUPPRESSANTS API MARKET SHARE BY END-USER, 2021 VS 2028 (%)
6. GLOBAL IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
7. GLOBAL CORTICOSTEROIDS IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
8. GLOBAL JANUS KINASE INHIBITOR IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
9. GLOBAL CALCINEURIN INHIBITORS IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
10. GLOBAL MTOR INHIBITOR IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
11. GLOBAL OTHERS IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
12. GLOBAL SYNTHETIC CHEMISTRY IN IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
13. GLOBAL PEPTIDE CHEMISTRY IN IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
14. GLOBAL FERMENTATION IN IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
15. GLOBAL CHROMATOGRAPHIC PURIFICATION IN IMMUNOSUPPRESSANTS API MARKET SHARE BY REGION, 2021 VS 2028 (%)
16. GLOBAL IMMUNOSUPPRESSANTS API IN AUTOIMMUNE DISEASE MARKET SHARE BY REGION, 2021 VS 2028 (%)
17. GLOBAL IMMUNOSUPPRESSANTS API IN ORGAN TRANSPLANT MARKET SHARE BY REGION, 2021 VS 2028 (%)
18. GLOBAL IMMUNOSUPPRESSANTS API TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
19. GLOBAL IMMUNOSUPPRESSANTS API CAPSULES MARKET SHARE BY REGION, 2021 VS 2028 (%)
20. GLOBAL IMMUNOSUPPRESSANTS API LIQUIDS MARKET SHARE BY REGION, 2021 VS 2028 (%)
21. GLOBAL IMMUNOSUPPRESSANTS API INJECTIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
22. GLOBAL IMMUNOSUPPRESSANTS API BY BIOTECHNOLOGY & BIOPHARMACEUTICAL COMPANY MARKET SHARE BY REGION, 2021 VS 2028 (%)
23. GLOBAL IMMUNOSUPPRESSANTS API BY CMOS MARKET SHARE BY REGION, 2021 VS 2028 (%)
24. GLOBAL IMMUNOSUPPRESSANTS API BY CROS MARKET SHARE BY REGION, 2021 VS 2028 (%)
25. GLOBAL IMMUNOSUPPRESSANTS API BY CDMOS MARKET SHARE BY REGION, 2021 VS 2028 (%)
26. GLOBAL IMMUNOSUPPRESSANTS API BY OTHER END-USERS MARKET SHARE BY REGION, 2021 VS 2028 (%)
27. US IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
28. CANADA IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
29. UK IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
30. FRANCE IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
31. GERMANY IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
32. ITALY IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
33. SPAIN IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
34. REST OF EUROPE IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
35. INDIA IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
36. CHINA IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
37. JAPAN IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
38. SOUTH KOREA IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
39. REST OF ASIA-PACIFIC IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
40. REST OF THE WORLD IMMUNOSUPPRESSANTS API MARKET SIZE, 2021-2028 ($ MILLION)
